| Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α Adrenoceptor Antagonists   
| Irreversible α antagonist (14-18 hours); inhibits reuptake of released norepinephrine; blocks histamine (H1), acetylcholine, and serotonin receptors; reduces BP when sympathetic tone is high (eg. standing up) | Orthostatic hypotension and tachycardia; nasal stuffiness and inhibition of ejaculation also occur; CNS symptoms – fatigue, sedation, nausea | Pheochromocytoma (tumor of the adrenal medulla or sympathetic ganglion cells that secretes catecholamines – symptoms include hypertension, headaches, palpitations, and increased sweating); occasionally Raynaud’s |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α Adrenoceptor Antagonists   
| Reversible; reduces peripheral resistance through blockade of α1 receptors and stimulates heart by antagonism of α2 receptors (↑ release of NE from sympathetic nerves) | Related to cardiac stimulation – severe tachycardia, arrhythmias, myocardial ischemia | Pheochromocytoma  |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α1 Adrenoceptor Antagonists   
| Reversible; highly selective for α1 receptors; relaxes smooth muscle in vessels and prostate (half-life 3 hours) | Relative absence of tachycardia, orthostatic hypotension may be severe after first few doses, dizziness first dose effect | Hypertension, occasionally Raynaud’s phenomenon and other conditions involving excessive reversible vasospasm, BPH   |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α1 Adrenoceptor Antagonists   
| Reversible α1 antagonist (half-life 9-12 hours) | Orthostatic hypotension first dose effect | Hypertension, benign prostatic hyperplasia (BPH) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α1 Adrenoceptor Antagonists   
| Reversible α1 antagonist (half-life 9-12 hours) | Orthostatic hypotension first dose effect | Hypertension, benign prostatic hyperplasia (BPH) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α1 Adrenoceptor Antagonists   
| Reversible α1 antagonist, higher affinity for α1A and α1D than for the α1B subtype; greater potency in inhibiting contraction in  prostate smooth muscle versus vascular | Less effect on standing BP first dose effect   | BPH  |      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α2 Adrenoceptor Antagonists   
| α2 selective antagonist; promotes NE release through blockade of presynaptic α2 receptors | Tachycardia, hypertension  | Orthostatic hypotension, used for erectile dysfunction (replaced by phosphodiesterase-5 inhibitors) |      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs β Adrenoceptor Antagonists   
| Block β1 and β2 receptors; lowers HR and BP, reduces renin; lipophilic crosses into CNS | Bradycardia, worsened asthma, fatigue, vivid dreams, cold hands | Hypertension, angina pectoris, arrhythmias, migraine, hyperthyroidism |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 10 Adrenoceptor-Antagonist Drugs α and β Antagonist   
| Reversible α antagonist; has both α1 selective and β-antagonistic effects; lowers BP with less limited HR increase | Less tachycardia than other α1 agents | Hypertension; hypertensive emergencies |    |  | 
        |  |